Mizuho Securities Remains a Buy on Xeris Pharmaceuticals (XERS)


In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals (XERS), with a price target of $14.00. The company’s shares closed last Thursday at $3.50.

According to TipRanks.com, Yang is ranked 0 out of 5 stars with an average return of -7.1% and a 36.1% success rate. Yang covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Sarepta Therapeutics, and Magenta Therapeutics.

Currently, the analyst consensus on Xeris Pharmaceuticals is a Strong Buy with an average price target of $10.50, implying a 204.3% upside from current levels. In a report issued on May 13, RBC Capital also maintained a Buy rating on the stock with a $10.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $7.94 and a one-year low of $2.45. Currently, Xeris Pharmaceuticals has an average volume of 2.37M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.

Read More on XERS:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts